论文部分内容阅读
[目的]探讨尿砷与乳腺癌的关联,并分析5,10-亚甲基四氢叶酸还原酶(MTHFR)rs1801133和甲硫氨酸合成酶(MTR)rs1805087多态性位点对其关联的影响。[方法]2009年10月至2010年7月对新诊断的240例乳腺癌患者及同时期同医院体检的246例年龄频数匹配对照进行问卷调查、尿样和血样收集。尿砷浓度采用电感耦合等离子体质谱(ICP-MS)检测;MTHFR rs1801133和MTR rs1805087基因型采用基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF-MS)方法,在Sequenom平台检测。[结果]病例组和对照组尿砷含量差异无统计学意义(P=0.32)。rs1801133和rs1805087在病例组和对照组中基因型分布差异无统计学意义(P>0.05)。rs1801133和rs1805087与砷对乳腺癌发生风险不存在交互作用(P>0.05)。[结论]在本研究人群中,未发现尿砷与乳腺癌风险有关联,MTHFR rs1801133和MTR rs1805087位点对该关联的影响也无统计学意义。
[Objective] To investigate the association between arsenic trioxide and breast cancer, and to analyze the association of 5,10-methylenetetrahydrofolate reductase (MTHFR) rs1801133 and methionine synthase (MTR) rs1805087 polymorphisms. influences. [Methods] From October 2009 to July 2010, 240 patients with newly diagnosed breast cancer and 246 age-matched controls who were examined in the same hospital at the same time were surveyed, urine samples and blood samples collected. Urinary arsenic concentrations were determined by inductively coupled plasma mass spectrometry (ICP-MS); MTHFR rs1801133 and MTR rs1805087 genotypes were detected using the matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MS) method on the Sequenom platform. [Results] There was no significant difference in urinary arsenic between the case group and the control group (P=0.32). There was no significant difference in genotype distribution between rs1801133 and rs1805087 in the case group and the control group (P>0.05). There was no interaction between rs1801133 and rs1805087 and arsenic in the risk of breast cancer (P>0.05). [Conclusion] In this study population, there was no association between urinary arsenic and breast cancer risk, and the impact of MTHFR rs1801133 and MTR rs1805087 loci on this association was also not statistically significant.